Select Your Location:
Global
France
Italy

Tislelizumab in Esophageal Squamous Cell Carcinoma

Tag: Solid Tumors

BeiGene is advancing a solid tumor pipeline consisting of novel oral small molecules and monoclonal antibodies for cancer. Among these are tislelizumab, a monoclonal antibody against PD-1 and ociperlimap, a monoclonal antibody against TIGIT.

RATIONALE-302 (NCT03430843) is a global Phase 3 study of tislelizumab vs investigator-chosen chemotherapy as a second-line (2L) treatment for advanced unresectable/metastatic esophageal squamous cell carcinoma (ESCC).

Reading
23 May 2025

RATIONALE-3O3 (NCT03358875) is an open-label, multicenter, randomized study of tislelizumab versus docetaxel in patients with non-small cell lung cancer (NSCLC) who have progressed on a prior platinum-containing regimen.

Reading
23 May 2025

RATIONALE-305 (NCT03777657) is a randomized, double-blind, placebo-controlled, global Phase 3 study of tislelizumab combined with platinum and fluoropyrimidine chemotherapy compared to placebo combined with platinum and fluoropyrimidine chemotherapy as a first-line treatment for patients with advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma (GC/GEJC).

Reading
23 May 2025

The RATIONALE-307 (NCT03594747), RATIONALE-304, (NCT03663205) and RATIONALE-303 (NCT03358875) trials were designed to evaluate the safety and efficacy of tislelizumab as a monotherapy and in combination with chemotherapy for the treatment of non-small cell lung cancer (NSCLC).

Reading
23 May 2025

Tislelizumab MoA

Tislelizumab (BGB-A317) is a humanized IgG4 monoclonal antibody designed to bind and inhibit PD‑1. Watch the mode of action (MoA) video to learn more.

Video
29 Apr 2025